RxDoctor Payments DataLook up a doctor →

Duc Tran, MD

Neurology · Dallas, TXNPI 1659477420

Payments from drug & device makers

$4,518,230in general payments, 2019–2025

Across 887 payments — averaging $5093.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.6M
  • Genentech, Inc.$473K
  • Alnylam Pharmaceuticals Inc.$187K
  • Alkermes, Inc.$69K
  • Lilly USA, LLC$58K
  • Biogen$57K
  • plus $44K from 54 others
$118,156in research payments, 2019–2025

Across 13 payments — averaging $9088.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$118K
  • AbbVie$115

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly35$3,629,949
Genentech, Inc.60$472,830
Alnylam Pharmaceuticals Inc.66$186,925
Alkermes, Inc.37$69,481
Lilly USA, LLC65$57,777
Biogen25$56,694
Avanir Pharmaceuticals, Inc.14$26,165
Merck4$6,346
AbbVie(2 entities)109$1,731
Novartis48$986
Eisai Inc.25$882
UCB, Inc.30$671
EMD Serono, Inc.12$621
Pfizer33$536
Acadia Pharmaceuticals Inc29$528
Genentech USA, Inc.21$435
Argenx US, Inc.9$307
Merz Pharmaceuticals, LLC9$305
AstraZeneca13$264
Teva Pharmaceuticals USA, Inc.11$246
Grifols USA, LLC11$242
Amgen(2 entities)12$233
Supernus Pharmaceuticals, Inc.15$231
Sunovion Pharmaceuticals Inc.14$206
Lundbeck LLC10$188
Ipsen Biopharmaceuticals, Inc8$173
Vanda Pharmaceuticals Inc.4$165
Biohaven Pharmaceutical Holding Company Ltd.11$164
Bristol Myers Squibb9$157
Neurocrine Biosciences, Inc.8$152
Neurelis, Inc.7$150
SK Life Science, Inc.7$139
CSL Behring7$132
Kyowa Kirin, Inc.5$113
Sumitomo Pharma America, Inc.5$111
Octapharma USA, Inc.5$111
Amneal Pharmaceuticals LLC6$111
Avion Pharmaceuticals7$102
Immedica Pharma US, Inc.3$99
Merz North America, Inc.3$93
Upsher-smith Laboratories LLC5$90
Adamas Pharmaceuticals, Inc.4$85
Sanofi4$85
Hospira, Inc.5$84
TG Therapeutics, Inc.4$78
Livanova USA, Inc.2$70
Catalyst Pharmaceuticals, Inc.3$64
Corium, LLC3$62
Acorda Therapeutics, Inc3$61
GE HealthCare5$56
Akcea Therapeutics, Inc.1$51
Johnson & Johnson(2 entities)3$49
Tanabe Pharma America, Inc.3$49
Takeda Pharmaceuticals U.S.A., Inc.2$48
Axsome Therapeutics, Inc.2$47
Jazz Pharmaceuticals Inc.2$40
Greenwich Biosciences, Inc.2$37
Scilex Pharmaceuticals Inc.2$35
Cycle Pharmaceuticals Inc1$34
Dompe US, Inc.1$32

How this compares

$4,518,230 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$301,400
Medicare patients
664
Services billed
4,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →